Literature DB >> 21719499

Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.

D Dumitrescu, C Seck, Henrik ten Freyhaus, F Gerhardt, E Erdmann, S Rosenkranz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21719499     DOI： 10.1183/09031936.00154210

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  23 in total

1.  Ligand-Independent Activation of Platelet-Derived Growth Factor Receptor β during Human Immunodeficiency Virus-Transactivator of Transcription and Cocaine-Mediated Smooth Muscle Hyperplasia.

Authors:  Pranjali N Dalvi; Vijayalaxmi G Gupta; Brooke R Griffin; Amy O'Brien-Ladner; Navneet K Dhillon
Journal:  Am J Respir Cell Mol Biol       Date:  2015-09       Impact factor: 6.914

2.  Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.

Authors:  J-C Kim; S-H Shin; H G Yi; S-H Kim; S-I Woo; D-H Kim; K-S Park; J Kwan
Journal:  Herz       Date:  2013-02-23       Impact factor: 1.443

Review 3.  Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword.

Authors:  Kuan-Liang Liu; Jen-Shi Chen; Shin-Cheh Chen; Pao-Hsien Chu
Journal:  Acta Cardiol Sin       Date:  2013-07       Impact factor: 2.672

Review 4.  Dasatinib-induced pulmonary arterial hypertension.

Authors:  Nurgül Özgür Yurttaş; Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2018-03-06       Impact factor: 4.335

5.  Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.

Authors:  Preetesh Jain; Hagop Kantarjian; Prajwal C Boddu; Graciela M Nogueras-González; Srdan Verstovsek; Guillermo Garcia-Manero; Gautam Borthakur; Koji Sasaki; Tapan M Kadia; Princy Sam; Hycienth Ahaneku; Susan O'Brien; Zeev Estrov; Farhad Ravandi; Elias Jabbour; Jorge E Cortes
Journal:  Blood Adv       Date:  2019-03-26

6.  A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer.

Authors:  Humera Khurshid; Thomas Dipetrillo; Thomas Ng; Kalyan Mantripragada; Ariel Birnbaum; David Berz; Kathy Radie-Keane; Kimberly Perez; Maria Constantinou; Denise Luppe; Andrew Schumacher; Kara Leonard; Howard Safran
Journal:  Front Oncol       Date:  2012-05-31       Impact factor: 6.244

7.  Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.

Authors:  Koung Jin Suh; Ji Yun Lee; Dong-Yeop Shin; Youngil Koh; Soo-Mee Bang; Sung-Soo Yoon; Seonyang Park; Inho Kim; Jeong-Ok Lee
Journal:  Int J Hematol       Date:  2017-04-04       Impact factor: 2.490

Review 8.  A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

Authors:  Elias Jabbour; Jeffrey H Lipton
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-10-01

9.  Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy.

Authors:  D J Deangelo
Journal:  Blood Cancer J       Date:  2012-10-19       Impact factor: 11.037

10.  A unified sparse representation for sequence variant identification for complex traits.

Authors:  Shaolong Cao; Huaizhen Qin; Hong-Wen Deng; Yu-Ping Wang
Journal:  Genet Epidemiol       Date:  2014-09-04       Impact factor: 2.135
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.